A
2.43
0.06 (2.53%)
| Penutupan Terdahulu | 2.37 |
| Buka | 2.50 |
| Jumlah Dagangan | 500,690 |
| Purata Dagangan (3B) | 1,655,090 |
| Modal Pasaran | 64,402,020 |
| Harga / Buku (P/B) | 5.38 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2025 - 18 Aug 2025 |
| EPS Cair (TTM) | -2.24 |
| Nisbah Semasa (MRQ) | 10.68 |
| Aliran Tunai Operasi (OCF TTM) | -22.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.95 M |
| Pulangan Atas Aset (ROA TTM) | -91.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -280.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Annovis Bio, Inc. | Bercampur | Menurun |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.69% |
| % Dimiliki oleh Institusi | 16.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Merit Financial Group, Llc | 31 Dec 2025 | 81,316 |
| First National Trust Co | 31 Dec 2025 | 40,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Dec 2025 | Pengumuman | Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients |
| 16 Dec 2025 | Pengumuman | Annovis to Host Corporate Update Webinar on January 28, 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |